Morichika Kazuho, Tomoyose Takeaki, Hanashiro Taeko, Shimabukuro Natsuki, Tamaki Keita, Tedokon Iori, Nishi Yukiko, Nakachi Sawako, Karube Ken-Nosuke, Fukushima Takuya, Katoh Takeharu, Ohshima Koichi, Masuzaki Hiroaki
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Japan.
Intern Med. 2016;55(10):1345-9. doi: 10.2169/internalmedicine.55.5997. Epub 2016 May 15.
Adult T cell leukemia / lymphoma (ATL) is one of the most aggressive hematological malignancies caused by human T-lymphotropic virus type-I (HTLV-1). Mogamulizumab is a new defucosylated humanized monoclonal antibody agent which targets C-C chemokine receptor type 4 (CCR4) expressed occasionally on the surface of ATL cells. However, adverse events such as drug eruptions have also been highlighted, at least in part, via the dysfunction of regulatory T cells (Tregs). We herein report a pronounced recurrence of systemic psoriasis vulgaris accompanied by the treatment of mogamulizumab in a patient with ATL. Pathological examinations may suggest a mechanistic link between the recurrence of autoinflammatory diseases and anti-CCR4 antibody therapies.
成人T细胞白血病/淋巴瘤（ATL）是由I型人类嗜T淋巴细胞病毒（HTLV-1）引起的最具侵袭性的血液系统恶性肿瘤之一。莫加莫单抗是一种新型去岩藻糖基化人源化单克隆抗体药物，其靶向偶尔在ATL细胞表面表达的C-C趋化因子受体4（CCR4）。然而，药物疹等不良事件也至少部分地通过调节性T细胞（Tregs）功能障碍而被凸显出来。我们在此报告1例ATL患者在接受莫加莫单抗治疗时出现全身性寻常型银屑病明显复发的情况。病理检查可能提示自身炎症性疾病复发与抗CCR4抗体治疗之间存在机制上的联系。
